Loading patent…
AssigneeMagenta Therapeutics, Inc.
InventorsRahul Palchaudhuri, Anthony Boitano, Michael Cooke, Bradley R. Pearse
Estimating the term…
The present disclosure provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.
An isolated anti-CD117 antibody, or antigen-binding fragment thereof, which binds to human CD117 at least at two of the following amino acid residues T67, K69, T71, S81, Y83, T114, T119, or K129 of CD117 listed in SEQ ID NO:
An isolated anti-CD117 antibody, or antigen-binding fragment thereof, capable of binding CD117 that binds to an epitope having residues within at least amino acids 67-83 and 114-129 of SEQ ID NO:
(canceled)
A pharmaceutical composition comprising an isolated anti-CD117 antibody, or antigen-binding fragment thereof, wherein, when bound to CD117, the antibody, or antigen-binding fragment thereof, binds to at least two of the following amino acid residues T67, K69, T71, S81, Y83, T114, T119, or K129 of CD117 listed in SEQ ID NO:
Dependencies are inferred from the claim text.